Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Toxicol Appl Pharmacol ; 293: 44-52, 2016 Feb 15.
Article in English | MEDLINE | ID: mdl-26780402

ABSTRACT

Doxorubicin (DOXO) is commonly used to treat a wide range of malignant tumors, but its clinical use is limited by acute and chronic cardiotoxicity. The precise mechanism underlying DOXO-induced cardiotoxicity is still not completely elucidated, but cardiac inflammation seems to be involved. Effects of DOXO on proinflammatory cytokines, inflammatory cell infiltration, and necrosis have been proven only when a functional impairment has already occurred, so this study aimed to investigate the acute effect of DOXO administration in mouse heart. The results of our study demonstrated alterations in cardiac function parameters assessed by ultrasound within 24h after a single injection of DOXO, with a cumulative effect along the increase of the dose and the number of DOXO administrations. At the same time, DOXO causes a significant production of proinflammatory cytokines (such as TNF-α and IL-6) with a concomitant reduction of IL-10, a well-known antiinflammatory cytokine. Furthermore, overexpression of inducible nitric oxide synthase (iNOS) in heart tissue and increased levels of serum nitrite in DOXO-treated mice were detected. Notably, DOXO administration significantly increased nitrotyrosine expression in mouse heart. Our data support the hypothesis that these early events, could be responsible for the later onset of more severe deleterious remodeling leading to DOXO induced cardiomyopathy.


Subject(s)
Antibiotics, Antineoplastic/adverse effects , Cardiotoxicity/metabolism , Doxorubicin/adverse effects , Animals , Cardiotoxicity/etiology , Cardiotoxicity/pathology , Disease Models, Animal , Echocardiography , Female , Interleukin-10/metabolism , Interleukin-6/metabolism , Mice, Inbred C57BL , Myocardium/metabolism , Myocardium/pathology , Nitric Oxide Synthase Type II/metabolism , Nitrites/metabolism , Tumor Necrosis Factor-alpha/metabolism , Tyrosine/analogs & derivatives , Tyrosine/metabolism
2.
Cardiovasc Toxicol ; 15(4): 366-76, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25552354

ABSTRACT

Doxorubicin is the highly effective anthracycline, but its clinical use is limited by cardiotoxicity and consequent dysfunction. It has been proposed that the etiology of this is related to mitochondrial dysfunction. Connexin 43 (Cx43), the principal protein building block of cardiac gap junctions and hemichannels, plays an important role in cardioprotection. Recent reports confirmed the presence of Cx43 in the mitochondria as well. In this study, the role of mitochondrial Cx43 was evaluated 3 or 6 h after Doxorubicin administration to the rat heart cell line H9c2. Pharmacological inhibition of Hsp90 demonstrated that the mitochondrial Cx43 conferred cardioprotection by reducing cytosolic and mitochondrial reactive oxygen species production, mitochondrial calcium overload and mitochondrial membrane depolarization and cytochrome c release. In conclusion, our study demonstrates that Cx43 plays an important role in the protection of cardiac cells from Doxorubicin-induced toxicity.


Subject(s)
Antibiotics, Antineoplastic/toxicity , Cardiomyopathies/chemically induced , Connexin 43/metabolism , Doxorubicin/toxicity , Mitochondria, Heart/drug effects , Myocytes, Cardiac/drug effects , Animals , Calcium Signaling , Cardiomyopathies/metabolism , Cell Line , Cytochromes c/metabolism , Dose-Response Relationship, Drug , HSP90 Heat-Shock Proteins/antagonists & inhibitors , HSP90 Heat-Shock Proteins/metabolism , Membrane Potential, Mitochondrial/drug effects , Mitochondria, Heart/metabolism , Myocytes, Cardiac/metabolism , Oxidative Stress/drug effects , Protein Transport , Rats , Reactive Oxygen Species/metabolism , Signal Transduction , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL